UK markets open in 6 hours 48 minutes
  • NIKKEI 225

    0.00 (0.00%)

    +177.11 (+0.91%)

    -0.32 (-0.40%)

    +5.20 (+0.22%)
  • DOW

    +134.19 (+0.34%)
  • Bitcoin GBP

    -566.53 (-1.07%)
  • CMC Crypto 200

    -19.41 (-1.41%)
  • NASDAQ Composite

    -12.33 (-0.07%)
  • UK FTSE All Share

    -10.47 (-0.23%)

Payday for Mike Lynch as Darktrace bought for £4.2bn

British technology tycoon Mike Lynch
Mr Lynch is currently facing criminal charges in the US related to the sale of his software company Autonomy - Yui Mok/PA

Mike Lynch, the British tech entrepreneur on trial over an alleged multi-billion dollar fraud, is in line for a £300m payday from the US takeover of cyber security company Darktrace.

The business is to be bought by private equity firm Thoma Bravo for £4.2bn in a deal that will deliver a financial boost to Mr Lynch, who owns almost 7pc of the company along with his wife Angela Bacares.

They have sold down their stake significantly in recent months but their holdings are worth £298m under the $7.75 (£6.20) a share takeover price.

Mr Lynch, a founding investor in Darktrace and former board member at the Cambridge based company, is in the middle of a US criminal trial over the $11bn sale of his technology company Autonomy in 2011.


Mr Lynch criticised the prospect of a Darktrace takeover two years ago when Thoma Bravo first considered buying the business. At the time he said US authorities’ “vindictive pursuit” of him had depressed the company’s share price and left it vulnerable, adding: “Another bright light in the British tech scene will be lost.

“The UK needs to stand up for its entrepreneurs and protect its economic and legal sovereignty, not be bullied by US interests.”

He did not comment on the sale on Friday.

Mr Lynch and Autonomy’s former finance director Stephen Chamberlain are six weeks into a San Francisco trial over fraud charges that can carry decades in prison. Both have pleaded not guilty and Mr Lynch is expected to testify in the coming weeks.

Mike Lynch, former chief executive officer of Autonomy Corp., center, arrives at federal court in San Francisco
Mr Lynch is expected to testify in the coming weeks - Loren Elliott/Bloomberg

Autonomy was sold to Hewlett Packard in 2011 but a year later HP executives accused the company’s former management of accounting improprieties.

Mr Lynch was charged in 2018, leading him to step down from Darktrace’s board and Mr Chamberlain to leave the company, where he was its chief operating officer.

Darktrace shares leapt by 17pc to 605p on Friday after the deal was announced.

Thoma Bravo said it would keep Darktrace’s Cambridge headquarters and its research operations in the UK.

Its chief executive Poppy Gustafsson, who stands to make almost £24m from the sale, will continue in her role.

Nicole Eagan, the company’s former chief executive, is due to make £69m from the deal.

The sale will be seen as another blow to the London Stock Exchange’s attempts to encourage technology companies, and comes just three years after Darktrace went public.

Announcing the deal, Darktrace said the company had been undervalued by stock market investors.

It said: “The Darktrace Board believes that Darktrace’s operating and financial achievements have not been reflected commensurately in its valuation with shares trading at a significant discount to its global peer group.”

Darktrace has had a dramatic three years as a listed company, with shares soaring amid a tech boom in 2021 before falling sharply as it was targeted by short sellers accusing the company of accounting improprieties, which it denied. The deal represents a 148pc premium to its flotation price.

Thoma Bravo, a $138bn private equity firm, specialises in tech and software businesses. It bought the London-listed cyber security company Sophos in 2020 in a $3.8bn deal.

A string of large companies have announced plans to come off the London Stock Exchange in recent months, either through a sale or pursuing an overseas listing. They include Flutter Entertainment, travel group Tui and building materials company CRH.

The British microchip giant Arm chose to list in New York rather than London last year. Earlier this month the chief executive of the British biotech company E-therapeutics said London’s markets were “completely broken and closed” as the company announced plans to de-list and pursue a US flotation.

Thoma Bravo said it had support from Darktrace’s biggest investor KKR, as well as Summit Partners, which own around 11.3pc between them.

More than a third of Mr Lynch’s shares are frozen by the US court system after he used them to meet bail demands after being extradited to America.